UndisclosedPrivate equity buyoutHealthcare & Life SciencesCompleted
Samfara buys Danish API maker Chr. Olesen Synthesis in debut deal
European life sciences investor Samfara completed its first investment, acquiring controlled-substance API manufacturer Chr. Olesen Synthesis from Chr. Olesen and Signet Healthcare Partners funds; terms undisclosed.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →